News & Media
-
May 31, 2025
Pre-surgical combination therapy shows promising results for NSCLC
UT MD Anderson News Release
-
May 2025
Dr Cascone was newly-elected At-Large Directors SITC 2025 Opens a new window
SITC press website
-
October 21, 2023
ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
UT MD Anderson News Release
-
September 14, 2023
Combination immunotherapy treatment effective before lung cancer surgery
UT MD Anderson News Release
-
March 16, 2023
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
UT MD Anderson News Release
-
May 5, 2022
Annual Meeting 2022: The New Frontier of Immunotherapy in Lung Cancer - Boosting the Immune Response Before Surgery. Opens a new window
Cancer Research Catalyst, The Official Blog of the American Association for Cancer Research
-
April 12, 2022
New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy Opens a new window
ASCO Post Interview
-
April 11, 2022
AACR: Combination immunotherapy treatment effective before lung cancer surgery
UT MD Anderson News Release
-
August 25, 2021
Neoadjuvant immunotherapy can produce nodal immune flair in lung cancer. -- Cascone T and Sepesi B. Opens a new window
Newswise. UT MD Anderson Research Highlights for August 25, 2021
-
June 20, 2021
Combo Immunotherapy Improves Outcomes for Early-Stage NSCLC Opens a new window
Oncology Times, Volume:43 Number 12, page 1,11 – 11
-
March 9, 2021
Phase II randomised study met prespecified primary endpoint threshold in patients with operable non-small cell lung cancer Opens a new window
ESMO Oncology News
-
February 18, 2021
Study reveals promising, less toxic treatments for patients with lung cancer. Opens a new window
Conquer Cancer. The ASCO Foundation News.
-
February 18, 2021
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer -- Cascone T and Sepesi B.
UT MD Anderson News Release
-
Nov. 20, 2020
UT MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting. Highlights include positive clinical data from combination therapies in patients with melanoma and lung cancer - Cascone T and Sepesi B.
UT MD Anderson News Release
-
Nov. 27, 2019
Remaining Challenges With Perioperative Immunotherapy in NSCLC. Opens a new window
OncLive Interview
-
June 2019
Toxicity Of Nivolumab and Ipilimumab: We're Still Learning How To Leverage These Treatments In The Pre-Operative Setting Opens a new window
OncologyTube Interview
-
June 11, 2019
Nivo/ipi shrinks early NSCLC before surgery Opens a new window
MedEdge Conference Coverage
-
June 6, 2019
Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung Cancer Opens a new window
Cancer Network Interview
-
June 2, 2019
Neoadjuvant Nivolumab/Ipilimumab Shows Promise in Resectable NSCLC Opens a new window
ASCO Daily News
-
June 1, 2019
ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers Opens a new window
ecancer
-
June 1, 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab Opens a new window
ecancer Interview
-
Aug. 5, 2018
Priming Immune System Prior to Surgery May Improve Outcomes Opens a new window
Oncology Times, August 5, 2018 - Volume 40 - Issue 15 - p 22,31.
-
July 26, 2016
Spotlight: What I Do As A Cancer Researcher Opens a new window
Lifehacker
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.